[HEROIN-LIKE SYNTHETIC SUBSTANCE 7-HYDROXYMITRAGYNANE TARGETED IN FEDERAL DRUG CRACKDOWN]
The Drug Enforcement Administration (DEA) announced plans Wednesday to temporarily classify 7-hydroxymitragynine (7-OH)—a synthetic opioid compound derived from kratom—under Schedule I drug regulations alongside heroin and LSD. The move marks a significant shift in federal policy after months of pressure from natural kratom industry stakeholders and political allies within the Trump administration.
The agency cited medical evidence showing 7-OH has “a significant potential for abuse and associated harms” while emphasizing its classification will specifically target synthetic iterations rather than natural kratom leaf products. The initial two-year provisional ban could become permanent or extended, with the DEA noting it will also apply to structurally similar compounds like MGM-15 currently marketed under deceptive packaging.
The policy change receives strong endorsement from White House figures including Health Secretary Robert F. Kennedy Jr., who praised the action as “decisive” against addictive substances. Homeland Security Secretary Markwayne Mullin—who holds a reported $1 million investment in kratom beverage manufacturer Botanic Tonics—characterized 7-OH products as “synthetic drugs marketed to kids via convenience store packaging.”
Prominent kratom advocacy groups welcomed the decision. Mac Haddow of the American Kratom Association stated, “This action should finally differentiate legitimate kratom products from dangerous opioid imitations masquerading as dietary supplements.” The DEA emphasized in its Federal Register notice that natural kratom forms remain unregulated under this directive.
Industry observers highlight potential enforcement challenges, as the 0.5% threshold for 7-OH content poses technical difficulties in field drug testing. Law enforcement agencies currently lack reliable methods to distinguish trace 7-OH content in natural kratom products from illicit synthetic versions.
Controversial financial entanglements continue to emerge: Mr. Mullin disclosed significant holdings in Botanic Tonics during his Senate nomination process, while advocacy groups supporting 7-OH restrictions maintained financial connections to Robert F. Kennedy Jr.’s political network. These ties fuel ongoing debates about regulatory motivations.
Critics warn against selective enforcement. Drug policy expert Kevin Sabet cautioned, “Singling out 7-OH while ignoring other kratom alkaloids creates misleading scientific narratives and regulatory vulnerabilities.” Similar criticism emerged from Shawn Van Buhler of the American Civil Liberties Union, noting potential legal loopholes in targeting only specific compounds.
Family advocates like Daniel Gibbs—whose son died from kratom overdose in 2023—expressed sharp skepticism about the policy’s practical implementation. “Neither parents nor law enforcement can realistically detect these substances,” he told reporters, calling the ban “purely political theater.” The DEA acknowledged these challenges in its implementation guidance but maintained the importance of measurable thresholds.
The distinction between kratom and its synthetic derivatives remains hotly contested, with companies like CBD American Shaman—the primary 7-OH product maker—planning legal challenges through consumer education campaigns. The White House has deferred comment, directing inquiries to the DEA’s enforcement timeline documentation.
